Avantor's Stock Decline Amid Prolonged Destocking Cycle

Broyhill Asset Management's first-quarter 2026 investor correspondence highlights a notable dip in the performance of Avantor, Inc.'s shares. The investment firm attributes this downturn to an extended inventory reduction phase within the company, surpassing initial projections, and an perceived failure by Avantor's leadership to effectively counter competition from Thermo Fisher. This situation led Broyhill to reallocate its investments from Avantor to Sotera Health, believing the latter offered a more compelling valuation and presented a strategic opportunity in the sterilization sector.

In their Q1 2026 communication to investors, Broyhill Asset Management specifically addressed the challenges faced by Avantor, Inc., a company based in Radnor, Pennsylvania, that supplies essential products and services to the biotechnology, education, and pharmaceutical industries. As of May 15, 2026, Avantor's stock was trading at $7.62 per share. The company's shares experienced a decline of 10.35% over the preceding month and a substantial 42.96% loss over the past 52 weeks, resulting in a market capitalization of $5.20 billion.

Broyhill Asset Management's decision to exit its Avantor position stemmed from concerns beyond just the prolonged destocking. The firm noted that successive management teams at Avantor had struggled to maintain market share against strong competitors like Thermo Fisher. This competitive pressure, combined with the inventory issues, prompted Broyhill to shift its capital. A portion of their Avantor stake was exchanged for Thermo Fisher shares last year, and the remaining investment was moved to Sotera Health. This strategic move was driven by the belief that Sotera Health, a duopoly in the critical sterilization market, offered a significant discount to its inherent value, particularly in light of ongoing litigation fears that had suppressed its stock price.

Despite Avantor, Inc.'s involvement in critical sectors, it did not appear on Broyhill's list of the 40 most favored stocks among hedge funds at the close of the fourth quarter. The number of hedge funds holding Avantor decreased from 50 in the previous quarter to 40. Avantor reported revenues of $1.58 billion in Q1 2026, marking a 4% organic decline and flat performance year-over-year on a reported basis. While acknowledging Avantor's potential, the investment firm suggested that certain artificial intelligence (AI) stocks offered superior upside potential with reduced downside risk, especially those poised to benefit from trade policies and domestic manufacturing trends.

The strategic shift by Broyhill Asset Management away from Avantor underscores a broader investment philosophy focused on identifying undervalued opportunities and responding dynamically to market and competitive pressures. This move reflects a calculated decision to prioritize assets with clear growth trajectories and resilient market positions, particularly in light of unexpected macroeconomic shifts and company-specific operational challenges.